HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: jmg.2006.048173v1 44/7/467    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kadouri, L. Articles by Peretz, T. Search for Related Content PubMed PubMed Citation Articles by Kadouri, L. Articles by Peretz, T. Pubmed/NCBI databases Gene GEO Profiles HomoloGene OMIM UniGene Medline Plus Health Information Breast Cancer Lymphoma Ovarian Cancer Genetics Home Reference

Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations

¹ Sharett Institute of Oncology, Hebrew University-Hadassah Medical Center, Jerusalem, Israel
² Department of Human Genetics Laboratories, Hebrew University-Hadassah Medical Center, Jerusalem, Israel

Correspondence to:
Dr L Kadouri
Sharett Institute of Oncology, Hadassah Medical Center, Jerusalem 91120, Israel; luna{at}hadassah.org.il] Background: The risks for cancers other than breast (BC) or ovarian (OC) cancer in breast cancer gene 1 and 2 (BRCA1/2) mutation carriers were elevated in studies of carrier families. However, case–control studies did not confirm this observation.

Objective: To compare the risks for other cancers in BRCA1/2 mutation carriers and non-carriers, all affected with BC and/or OC. Both groups share risk modifiers of BC/OC, which enabled assessment of the role of BRCA1/2 mutations.

Methods: 1098 Ashkenazi Jewish women affected with BC and/or OC were ascertained during 1995–2003; molecular testing revealed 229 BRCA1 and 100 BRCA2 carriers and 769 non-carriers. COX proportional hazard models were used to evaluate the risk of other cancers. Analyses were conducted including all other cancers or only those diagnosed after BC/OC diagnosis.

Results: The HRs for any other cancer were 2.6 (95% CI 1.7 to 4.2, p<0.001) and 1.8 (95% CI 0.95 to 3.6, p = 0.07) in BRCA1 and BRCA2 carriers, respectively. The corresponding colon cancer HRs were 3.9 (95% CI 1.3 to 12.1, p = 0.02) and 2.3 (95% CI 0.5 to 11.3, p = 0.3) in BRCA1 and BRCA2 carriers. The HR for lymphoma was 11.9 (95% CI 3.1 to 46.2, p = 0.001) in BRCA2 carriers. Risk estimates for other cancers after the onset of BC/OC were similar.

Conclusion: A 2.5-fold increase in any other cancer and a fourfold risk of colon cancer were found among BRCA1 carriers. The corresponding HRs in BRCA2 carriers were non-significant, except for the markedly elevated risk of lymphoma. These results suggest a role for BRCA1/2 mutations in colorectal cancer risk in a subgroup of BC/OC-affected carriers.

Abbreviations: BC, breast cancer; BCLC, Breast Cancer Linkage Consortium; BRCA1/2, breast cancer genes 1 and 2; CC, colon cancer; HR, hazard ratio; OC, ovarian cancer; RR, relative risk